Dr. Pravin U. Dugel: Anatomy in HAWK and HARRIER
Retina Subspecialty Day Coverage – American Academy of Ophthalmology 2018
Series: 2018
Retina Subspecialty Day Coverage – American Academy of Ophthalmology 2018
Series: 2018
Pravin U. Dugel, MD Channels: Retina
Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the 48-week data, focusing in particular on anatomic results.